LifeStance Health vs Pennant
LFST and PNTG side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LFST and PNTG compare
LifeStance Health is the larger company, worth 4.3 times as much as Pennant ($5.4B against $1.3B).
On earnings, Pennant is cheaper: it trades at 36.4× trailing earnings, against 74.1× for LifeStance Health.
Pennant grew revenue faster over the last twelve months (38.7% versus 22.6% for LifeStance Health).
LifeStance Health keeps more of each dollar of sales as profit, with a net margin of 4.3% compared with 3.1% at Pennant.
Pennant scores higher on the StockData Score (14 against 12 for LifeStance Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LFST | PNTG |
|---|---|---|
| Size and price | ||
| Market cap | $5.4B | $1.3B |
| Share price | $14.08 | $36.07 |
| Change, 1 year | 119% | 42.9% |
| Change, 5 years | 62.8% | 60.2% |
| Beta (5Y) | 1.17 | 1.06 |
| Employees | 11K | 9,700 |
| StockData Score | ||
| Total score | 12 | 14 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 3 | 4 (better) |
| Performance score | 3 | 3 |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 74.1× | 36.4× (better) |
| P/S | 3.2× | 1.1× (better) |
| P/B | 3.6× | – |
| EV/EBITDA | 36.7× | 16.1× (better) |
| P/FCF | 30.0× (better) | 36.7× |
| PEG | – | 0.65 |
| FCF yield | 3.3% (better) | 2.7% |
| Fair value | $5.88 | $37.49 |
| Margin of safety | −139% | 3.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 22.6% | 38.7% (better) |
| Revenue growth, 5Y average | – | 19.4% |
| Net income growth (TTM) | – | 34.4% |
| EPS growth (TTM) | – | 32.0% |
| EPS growth, 5Y average | – | 10.1% |
| Profitability | ||
| Gross margin | – | 18.3% |
| Operating margin | 6.2% (better) | 5.8% |
| Net margin | 4.3% (better) | 3.1% |
| FCF margin | 10.7% (better) | 2.9% |
| Return on equity | 4.8% | – |
| Return on invested capital | 5.4% | – |
| Financial health | ||
| Debt / equity | 0.18 | – |
| Net debt / EBITDA | 0.35 (better) | −0.17 |
| Interest coverage | 10.6× (better) | 5.2× |
| Current ratio | 1.44 (better) | 1.18 |
| Altman Z-score | 5.16 (better) | 2.74 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 98.7% | 92.7% |
| Held by insiders | 64.6% | 5.0% |
| Insider net buying, 12 months | −$849M | −$690K (better) |
| Short interest, % of float | 10.1% | 3.5% |
Go deeper
- LFST stock overview
- LFST income statement
- LFST valuation and score
- PNTG stock overview
- PNTG income statement
- PNTG valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.